Tumor Suppressor Gene P53 (TP53) Gene Mutation Analysis
The TP53 gene is located on the short arm of chromosome 17 (17p13.1), and codes a nuclear DNA-binding protein that regulates cell growth and proliferation. p53 is a transcription factor protein with 393 amino acids that acts as tumor suppressor responsible for DNA repair, cell cycle arrest, and apoptosis. Therefore, p53 plays a critical role in cells throughout the body and has been called the guardian of the genome. If DNA in a cell becomes damaged, p53 binds to the DNA and activates several other genes to fix the damage. If the damage cannot be repaired, it will prevent the cell from dividing and signal it to undergo apoptosis (self-destruction). This activity prevents mutated cells from dividing, which helps prevent the proliferation of neoplastic cells (tumors). There are five domains of the protein that are highly conserved between species. Activated p53 itself activates many genes but the end result of cell cycle arrest in either the G1 or G1 phase or cell apoptosis.
Normal p53 is referred to as "wild type" p53, whereas mutated p53 is referred to as "mutant p53". Under normal conditions, wild type p53 (wtp53) would inhibit cell growth. The cell regulates this by exporting p53 from the nucleus to the cytoplasm for degradation. When DNA damage occurs, a phosphate attaches to the p53 protein, preventing it from leaving the nucleus. This allows p53 to accumulate and perform its normal useful function. Mutations of the p53 gene, however, change the protein’s function by making the protein resistant to degradation and leading to accumulation in the nucleus of the mutant p53 and promoting cell proliferation and cancer. Overexpression or accumulation of this protein is associated with a poor prognosis in a wide variety of tumors. Mutations in p53 are found in about 40% of all human cancers, and so contribute to the complex network of molecular events leading to tumor formation.
The human papilloma virus encodes a protein called E6 which binds p53 and inactivates it. Alterations of this gene occur not only as somatic mutations but also as germ line mutations including colorectal, breast, prostate, lung, brain and bladder cancer. Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder characterized by a germline mutation of p53. Patients with this syndrome most often develop (before the age of 10) soft tisue sarcomas, brain tumors, adrenocortical carcinomas, osteosarcoma (adolescents) and breast cancer (adult females). Some LFS patients do not have a mutation of the p53 gene, but instead have mutations involving genes of the p53 pathway (e.g., CHK2 and PTEN). Testing for p53 genetic mutation by IHC can assist in disease (cancer) management (therapy treatment) and prognosis. Efforts are underway to develop therapeutic substances to reactivate the p53 pathway which will lead to tumor cell death.
- Screening for p53 mutation in families with a high risk of cancer or family history of cancer (esophagus, stomach, colon, rectal, prostate, breast, lung and bladder)
- As an aid in diagnosis and management of Li-Fraumeni syndrome
- Disease management, prognosis and therapy treatment
- Therapy monitoring and management
- As an aid in evaluation of several cancer types (lung, colon and pancreatic)
Mutation not detected (Negative for mutations analyzed)
FFPE blocks and slides, sent at 20-25°C, protect from heat. Include a copy of Surgical Pathology report.
Whole Blood samples collected in tubes with anticoagulant (lavender top tube), received within 72 hours at 20-25°C temperature. Store at refrigeration for 7 days.
Saliva, 2mL, ship at 20-25°C.
- J Urol. 2003 Apr;169(4):1219-28. [PMID: 12629332]
- Cancer, 1992, 70(12):2778-84. [PMID: 1451055]
- Br J Cancer, 1992, 66(3):558-62. [PMID: 1520594
- J Natl Cancer Inst, 1993, 85(3):200-6. [PMID: 8423624]
- J Natl Cancer Inst, 1992, 84(11):845-55. [PMID: 1317462]
- J Natl Cancer Inst, 1993, 85(1):53-9. [PMID: 7677935]
- Med Mol Morphol. 2012 Jun;45(3):115-23. [PMID: 23001293]